A phase II study to determine the efficacy, safety, tolerability, and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with attention-deficit/hyperactivity disorder (ADHD)
Journal of the American Academy of Child & Adolescent Psychiatry | Oct 29, 2017
Most read this week